Digital Look

Welcome to Digital Look++,
you are not logged in

Tissue Regenix Group (TRX)

Financials

7.25p

2025-10-22 Suspension On Listing

Year Ending	Revenue ($m)	Pre-tax ($m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
31-Dec-20	16.47	(13.15)	(28.00)¢	n/a	n/a	n/a	n/a	0.0%
31-Dec-21	19.75	(5.14)	(7.00)¢	n/a	n/a	n/a	n/a	0.0%
31-Dec-22	24.48	(2.83)	(3.83)¢	n/a	n/a	n/a	n/a	0.0%
31-Dec-23	26.32	(1.89)	(2.67)¢	n/a	n/a	n/a	n/a	0.0%
31-Dec-24	28.65	(0.56)	(1.20)¢	n/a	n/a	n/a	n/a	0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Statement re. Suspension	22-Oct-2025	15:29	RNS
Suspension - Tissue Regenix Group PLC	22-Oct-2025	14:02	RNS
CFO joins Board	17-Oct-2025	07:00	RNS

Tissue Regenix CFO joins board	17-Oct-2025	ShareCast
Tissue Regenix gets CE, UKCA certifications for ...	09-Jun-2025	ShareCast
Tissue Regenix flags first half in line with exp...	16-Jul-2024	ShareCast

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.